Helus Pharma
Develops investigational serotonergic therapies for depression and generalized anxiety disorder.
Something off on this page? Send us feedback.
Profile
Develops investigational serotonergic agonists for major depressive disorder and generalized anxiety disorder. Its lead programs, HLP003 and HLP004, remain in clinical development, with HLP003 in Phase 3 and HLP004 following a Phase 2 signal-detection study.
Advances HLP003, an adjunctive treatment candidate for major depressive disorder, through the Phase 3 PARADIGM program. APPROACH, EMBRACE, and the EXTEND long-term extension study form that program; HLP003 has FDA Breakthrough Therapy Designation.
Develops HLP004 for generalized anxiety disorder following a Phase 2 signal-detection study, while HLP005 remains before candidate selection. The portfolio is built around novel serotonergic agonists rather than commercial products.
Operates as Helus Pharma while Cybin Inc. remains the legal issuer. The security moved from NYSE American's CYBN to Nasdaq's HELP in 2026, and progress toward commercialization depends on study execution and regulatory approvals.
Company facts
Key statistics
Year to date +46.9% · Average volume (30d) 1.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Jul 27, 2026 | Wells Fargo | Initiate | Overweight | $16 |
| Jul 14, 2026 | Industrial Alliance Securities | Target | $15 | |
| Feb 1, 2026 | Jefferies | Target | $22 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q1 FY27 | −$0.84 | −$0.91 | −8.8% | — | — | — | +4.72% |
| Jun 30, 2026Q4 FY26 | −$1.04 | −$0.96 | +7.8% | $1.3M | $1.3M | 0.0% | −4.99% |
| Feb 16, 2026Q3 FY26 | −$0.76 | −$0.99 | −30.5% | — | — | — | +11.00% |
| Feb 13, 2026Q3 FY26 | −$0.53 | −$0.72 | −35.8% | — | — | — | +11.00% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | −$30.2K | |
| Operating income | −$33.3M | −$24.6M | −$40.3M | −$41.2M | −$47.9M | −$47.8M | |
| Net income | −$30.6M | −$24.6M | −$47.0M | −$42.6M | −$47.0M | −$46.6M | |
| Diluted EPS | −$1.46 | −$1.10 | −$1.94 | −$1.76 | −$0.92 | −$0.89 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0 · FY26 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $166.2M · Total debt $0 · Total assets $259.3M · Shareholders' equity $241.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 61.98M · Float 48.69M · 78.6% free float
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Definium Therapeutics
Phase 3 lysergide programs in both MDD and GAD
- Compass Pathways (ADR)
Late-stage synthetic psilocybin program for resistant depression
- GH Research
Inhaled mebufotenin program for treatment-resistant depression
- Atai Beckley
Multiple rapid-acting programs for resistant depression
- Incannex Healthcare
Oral synthetic psilocybin program for generalized anxiety disorder
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Helus Pharma | $12.35 | +1.56% | $755.0M | — | — | — | — |
| Definium Therapeutics | $41.00 | +0.05% | $5.44B | — | — | — | — |
| Compass Pathways (ADR) | $13.79 | +0.56% | $1.85B | — | — | — | — |
| GH Research | $28.16 | +1.04% | $1.92B | — | — | — | — |
| Atai Beckley | $7.29 | 0.00% | $2.70B | — | — | 602.9 | +137.0% |
| Incannex Healthcare | $3.66 | +0.27% | $43.6M | — | — | 653.8 | +1,566.7% |
| Median | — | — | 628.4 | +851.8% |